Overview

A Study of HS-10380 in Chinese Participants

Status:
Not yet recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.